Want to see IN:VIVIMEDLAB full AI Analyst Report?
VIVIMEDLAB Stock Chart & Stats
₹4.95
₹0.00(0.00%)
At close: 4:00 PM EDT
₹4.95
₹0.00(0.00%)
Day’s Range― - ―
52-Week Range₹4.88 - ₹27.99
Previous CloseN/A
Volume151.69K
Average Volume (3M)N/A
Market Cap
₹428.66M
Enterprise Value₹4.24K
Total Cash (Recent Filing)₹13.56M
Total Debt (Recent Filing)₹3.97B
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.28
Shares Outstanding82,913,910
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.22
Price to Sales (P/S)0.66
P/FCF Ratio6.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API Supply To Regulated MarketsSupplying APIs and intermediates into regulated and semi-regulated markets is a durable business model: recurring B2B demand, long customer qualification cycles, and regulatory entry barriers create structural stickiness and higher switching costs than commodity suppliers.
Recent Cash-flow RecoveryA return to positive operating and free cash flow in 2026 materially improves near-term liquidity and gives management options to reduce leverage, fund working capital, or invest in compliance/capacity — a fundamental improvement versus prior cash drain.
Contract Manufacturing & Export ExposureHaving contract manufacturing capabilities and export channels diversifies revenue sources beyond spot API sales, enabling longer-term supply agreements, better capacity utilisation and foreign-currency revenue that can bolster durability when executed consistently.
Bears Say
Shrinking Revenue & Negative MarginsPersistent multi-year revenue declines combined with a recent turn to negative gross profit indicate structural pricing pressure or rising input costs. This undermines scale economics and suggests the company lacks durable pricing power in core products and markets.
Negative Equity And High DebtNegative equity shows accumulated losses have eroded capital. High, sustained debt with an impaired equity base restricts strategic flexibility, raises refinancing and covenant risk, and limits ability to fund capex or absorb further shocks over the medium term.
Volatile And Inconsistent Cash GenerationHistoric swings in operating cash flow and sharply negative free cash flow growth reduce predictability of internal funding. That volatility weakens the sustainability of recent cash improvements and raises execution risk for any turnaround or investment plans.
Vivimed Labs Limited News
VIVIMEDLAB FAQ
What was Vivimed Labs Limited’s price range in the past 12 months?
Vivimed Labs Limited lowest stock price was ₹4.88 and its highest was ₹27.99 in the past 12 months.
What is Vivimed Labs Limited’s market cap?
Vivimed Labs Limited’s market cap is ₹428.66M.
When is Vivimed Labs Limited’s upcoming earnings report date?
Vivimed Labs Limited’s upcoming earnings report date is Nov 12, 2026 which is in 102 days.
How were Vivimed Labs Limited’s earnings last quarter?
Currently, no data Available
Is Vivimed Labs Limited overvalued?
According to Wall Street analysts Vivimed Labs Limited’s price is currently Overvalued.
Does Vivimed Labs Limited pay dividends?
Vivimed Labs Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on Vivimed Labs Limited dividends here
What is Vivimed Labs Limited’s EPS estimate?
Vivimed Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivimed Labs Limited have?
Vivimed Labs Limited has 82,913,910 shares outstanding.
What happened to Vivimed Labs Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivimed Labs Limited?
Currently, no hedge funds are holding shares in IN:VIVIMEDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivimed Labs Limited
Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug formulations, specialized chemicals, and consumer-branded remedies. Its global presence extends across markets such as India, Mexico, Spain, and Hungary, among others. The company's operations are divided into two core segments: the Pharmaceutical Business and the Specialty Chemicals Business. Within its Pharmaceutical division, Vivimed Labs supplies APIs and crucial intermediates to both generic and ethical pharmaceutical companies. It also develops and markets proprietary branded formulations catering to therapeutic areas like ophthalmology, nutraceuticals, dermatology, and pain relief. Additionally, it provides contract manufacturing services for a variety of dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments. A notable product is Favulous, manufactured for the treatment of mild to moderate COVID-19 cases. The Specialty Chemicals segment boasts a broad portfolio. This includes Jarocol-branded hair dye intermediates essential for permanent, semi-permanent, and temporary hair coloring systems, alongside oxidation dye couplers, bases, and direct and basic dyes. It also produces Reversacol-branded photochromic dyes and antimicrobial agents utilized in applications ranging from plastic additives to antibacterial handwashes. Furthermore, the company manufactures photographic chemicals, such as black and white developers and antifog additives, for medical and industrial X-ray imaging, consumer photography, and graphic arts litho-plate production. Collectively, Vivimed Labs' offerings find extensive application in the home, personal, and industrial care sectors.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―



